Barclays PLC Geron Corp Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Geron Corp stock. As of the latest transaction made, Barclays PLC holds 1,528,749 shares of GERN stock, worth $3.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,528,749

Previous 1,299,912 17.6%

Holding current value

$3.93 Million

Previous $5.9 Million 8.3%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$3.3 - $4.44 $755,162 - $1.02 Million	228,837 Added 17.6%	1,528,749 $5.41 Million
Q3 2024 Nov 15, 2024	BUY	$4.17 - $4.99 $2.9 Million - $3.47 Million	694,931 Added 114.87%	1,299,912 $5.9 Million
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $116,925 - $191,984	37,718 Added 6.65%	604,981 $2.57 Million
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $1.76 Million - $3.47 Million	-1,008,322 Reduced 64.0%	567,263 $1.87 Million
Q4 2023 Feb 15, 2024	BUY	$1.74 - $2.31 $19,550 - $25,955	11,236 Added 0.72%	1,575,585 $3.33 Million
Q3 2023 Nov 07, 2023	BUY	$2.11 - $3.28 $1.71 Million - $2.66 Million	811,192 Added 107.71%	1,564,349 $3.32 Million
Q2 2023 Aug 03, 2023	SELL	$1.97 - $3.69 $72,553 - $135,899	-36,829 Reduced 4.66%	753,157 $2.42 Million
Q1 2023 May 04, 2023	SELL	$2.14 - $3.4 $289,368 - $459,744	-135,219 Reduced 14.62%	789,986 $1.71 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $1.16 Million - $1.38 Million	569,474 Added 160.09%	925,205 $2.24 Million
Q3 2022 Nov 03, 2022	BUY	$1.67 - $2.94 $563,957 - $992,835	337,699 Added 1872.78%	355,731 $833,000
Q2 2022 Aug 12, 2022	SELL	$1.19 - $1.65 $38,745 - $53,722	-32,559 Reduced 64.36%	18,032 $28,000
Q1 2022 May 16, 2022	SELL	$0.99 - $1.6 $316,147 - $510,945	-319,341 Reduced 86.32%	50,591 $69,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $285,770 - $402,889	234,238 Added 172.62%	369,932 $452,000
Q3 2021 Nov 09, 2021	BUY	$1.2 - $1.5 $104,890 - $131,113	87,409 Added 181.03%	135,694 $186,000
Q2 2021 Aug 13, 2021	SELL	$1.25 - $1.83 $244,305 - $357,662	-195,444 Reduced 80.19%	48,285 $67,000
Q1 2021 May 13, 2021	BUY	$1.52 - $2.1 $222,804 - $307,822	146,582 Added 150.89%	243,729 $385,000
Q4 2020 Feb 11, 2021	SELL	$1.55 - $2.05 $53,333 - $70,538	-34,409 Reduced 26.16%	97,147 $154,000
Q3 2020 Nov 12, 2020	SELL	$1.59 - $2.19 $14,683 - $20,224	-9,235 Reduced 6.56%	131,556 $229,000
Q2 2020 Aug 12, 2020	BUY	$1.05 - $2.18 $44,980 - $93,389	42,839 Added 43.73%	140,791 $306,000
Q1 2020 May 13, 2020	SELL	$0.89 - $1.49 $113,050 - $189,264	-127,023 Reduced 56.46%	97,952 $116,000
Q4 2019 Feb 10, 2020	BUY	$1.27 - $1.54 $118,643 - $143,866	93,420 Added 71.01%	224,975 $306,000
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $18,811 - $26,009	16,358 Added 14.2%	131,555 $175,000
Q2 2019 Aug 14, 2019	BUY	$1.37 - $2.02 $88,508 - $130,502	64,605 Added 127.7%	115,197 $162,000
Q1 2019 May 15, 2019	SELL	$1.01 - $1.83 $148,739 - $269,498	-147,267 Reduced 74.43%	50,592 $84,000
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $36,489 - $68,882	-37,234 Reduced 15.84%	197,859 $198,000
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $393,236 - $1.43 Million	223,430 Added 1915.72%	235,093 $413,000
Q2 2018 Aug 14, 2018	SELL	$3.29 - $4.82 $138,416 - $202,787	-42,072 Reduced 78.3%	11,663 $40,000
Q1 2018 May 15, 2018	SELL	$1.81 - $5.98 $3,408 - $11,260	-1,883 Reduced 3.39%	53,735 $228,000
Q4 2017 Feb 14, 2018	SELL	$1.8 - $2.32 $162,104 - $208,934	-90,058 Reduced 61.82%	55,618 $100,000
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $289,895 - $386,041	145,676	145,676 $319,000

Others Institutions Holding GERN

# of Institutions

306

Shares Held

465M

Call Options Held

1.07M

Put Options Held

648K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $971M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account